WallStSmart

Akso Health Group ADR (AHG)vsHong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Akso Health Group ADR generates 10% more annual revenue ($14.84M vs $13.43M). AHG leads profitability with a 0.0% profit margin vs -8.5%. HKPD earns a higher WallStSmart Score of 26/100 (F).

AHG

Avoid

16

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 6.0Quality: 9.0
Piotroski: 5/9Altman Z: 12.00

HKPD

Avoid

26

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 3/9Altman Z: 3.84
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHGUndervalued (+17.1%)

Margin of Safety

+17.1%

Fair Value

$1.70

Current Price

$1.35

$0.35 discount

UndervaluedFair: $1.70Overvalued

Intrinsic value data unavailable for HKPD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHG2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
12.0010/10

Safe zone — low bankruptcy risk

HKPD2 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
3.8410/10

Safe zone — low bankruptcy risk

Areas to Watch

AHG4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.9%4/10

0.9% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.37B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

HKPD4 concerns · Avg: 2.5/10
Market CapQuality
$9.87M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

Revenue GrowthGrowth
-31.7%2/10

Revenue declined 31.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : AHG

The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.

Bull Case : HKPD

The strongest argument for HKPD centers on Price/Book, Altman Z-Score.

Bear Case : AHG

The primary concerns for AHG are Revenue Growth, EPS Growth, Market Cap.

Bear Case : HKPD

The primary concerns for HKPD are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

AHG profiles as a value stock while HKPD is a turnaround play — different risk/reward profiles.

AHG is growing revenue faster at 0.9% — sustainability is the question.

HKPD generates stronger free cash flow (-279,450), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HKPD scores higher overall (26/100 vs 16/100). AHG offers better value entry with a 17.1% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akso Health Group ADR

HEALTHCARE · MEDICAL DISTRIBUTION · China

Akso Health Group ADR is a leading entity in the healthcare sector, dedicated to providing innovative medical solutions and comprehensive patient care services. With a strong emphasis on advanced health technologies, the company is strategically positioned in the telehealth and personalized medicine markets, supported by a robust research and development framework. As it navigates the rapidly evolving healthcare landscape, Akso Health Group presents an attractive investment opportunity for institutional investors seeking to capitalize on transformative trends within the industry.

Visit Website →

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Hong Kong Pharma Digital Technology Holdings Limited is a pioneering entity in the biotechnology and digital healthcare sectors, focused on enhancing patient outcomes through innovative pharmaceutical services. By harnessing cutting-edge digital technologies and sophisticated data analytics, the company optimizes drug development and boosts operational efficiencies, positioning itself as a key player in the dynamic healthcare landscape. With a commitment to health technology advancement and strategic collaborations, Hong Kong Pharma is well-equipped to meet the evolving needs of both domestic and international markets while propelling innovation within its extensive service offerings.

Want to dig deeper into these stocks?